Medical Advocates
ART/HAART/cART
  Treatment Interruption Journal Citations

 General Reports/Studies
Retrospective Studies
 Viral Dynamics
 Resistance
 Adverse Events


 
Treament Interruption Main Page Main New/Newsworthy Home Page      
Last Update:  January 16, 2018
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports/Studies
     
 
Post treatment controllers after treatment interruption in chronically HIV infected patients.
 Maggiolo F, Di Filippo E, Comi L, Callegaro A.
 AIDS. 2018 Jan 13.
 Abstract

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
 Calin R, Hamimi C, Lambert-Niclot S, Carcelain G, et al
AIDS. 2016 Jan 4.
 Abstract

On the role of resonance in drug failure under HIV treatment interruption.
Oña L, Kouyos RD, Lachmann M, Bonhoeffer S.
Theor Biol Med Model. 2013 Jul 11;10(1):44.
 Abstract

Platelet count kinetics following Interruption of antiretroviral treatment: Results from the SMART study.
Zetterberg E, Neuhaus J, Baker JV,  et al
AIDS. 2012 Sep 26..
 Abstract

Evaluation of HIV-1 Ambiguous Nucleotide Frequency during Antiretroviral Treatment Interruption.
 Li JZ, Christensen JA, Wang H,  et al
J Acquir Immune Defic Syndr. 2012 Jun 22
 Abstract

FULL-TEXT ARTICLE
 HIV Reservoirs and Immune Surveillance Evasion Cause the Failure of Structured Treatment Interruptions:
A Computational Study.
 Mancini E, Castiglione F, Bernaschi M, et al
PLoS One. 2012;7(4):e3610
 Paper

ART interruptions result in loss of protective humoral immunity to neo-antigens in HIV-infected
individuals.
Azzoni L, Foulkes AS, Firnhaber C,  et al
 AIDS. 2012 Apr 18.
 Abstract

FULL-TEXT ARTICLE
 Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant
HIV Infection from the OPTIMA Trial.
 Holodniy M, Brown ST, Cameron DW, et al.  
PLoS ONE 6(3): e14764
 Paper

FULL-TEXT ARTICLE
 Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the
Viral Setpoint upon Treatment Interruption.
von Wyl V, Gianella S, Fischer M,  et al
PLoS One. 2011;6(11):e27463.
 Paper

Unstructured treatment interruption of antiretroviral therapy in clinical practice:
a systematic review.
Kranzer K, Ford N.
Trop Med Int Health. 2011 Jul 1.
Abstract

Immunological Analysis of Treatment Interruption After Early Highly Active
Antiretroviral Therapy.
 Schellens IM, Pogany K, Westerlaken GH, et al
Viral Immunol. 2010 Dec;23(6):609-61
 Abstract

Switching of HIV inferred tropism during interruption of antiretroviral therapy.
Sarmati L, Parisi SG, Andreoni C,  et al  
J Clin Microbiol. 2010 May 19.
Abstract

Predictive Value of Intracellular HIV-1 DNA Levels During CD4-Guided
Treatment Interruption in HIV(+) Patients.
Nasi M, Pinti M, Manzini S, Gibellini L, et al
AIDS Res Hum Retroviruses. 2010 May 10
 Abstract

FULL-TEXT ARTICLE
HIV drug breaks may be tolerated
Miron RE, Smith RJ 
BMC Infectious Diseases 2010, 10:6
 Paper

Magnitude and determinants of CD4 recovery after HAART resumption after 1
cycle of treatment interruption.
Mussini C, Touloumi G, Bakoyannis G, et al
J Acquir Immune Defic Syndr. 2009 Dec;52(5):588-94.
 Abstract

Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified
trial of intentionally interrupted treatment.
Volberding P, Demeter L, Bosch RJ, et al
 AIDS. 2009 Aug 19.
Abstract

Structured treatment interruption in HIV-infected adolescents.
Vidal P, Lalande M, Rodiere M.
 Arch Pediatr. 2009 Apr 13.
Abstract

Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
 Sarmati L, Andreoni C, Nicastri E, et al 
J Med Virol. 2009 Jan 16;81(3):481-487
 Abstract
 
CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic
response to HAART.
Maggiolo F, Airoldi M, Callegaro A, eu al
 AIDS. 2008 Dec 24.
Abstract
 
CD4+ Guided Antiretroviral Treatment Interruption in HIV Infection: A Meta-Analysis.
Seminari E, De Silvestri A, Boschi A, Tinelli C.
 AIDS Rev. 2008 Oct-Dec;10(4):236-44.
 Abstract
 
Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in
HIV-Infected Patients With Immune Preservation: Results of ACTG 5170.
Skiest DJ, Krambrink A, Su Z, et al 
J Acquir Immune Defic Syndr. 2008 Oct 16.
 Abstract
 
FULL-TEXT ARTICLE
 Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at
low-to-moderate adherence levels.
 Parienti JJ, Das-Douglas M, Massari V, et al
PLoS ONE. 2008 Jul 30;3(7):e2783.
 Paper
 
Lipid and Apoprotein Profile in HIV-1-Infected Patients After CD4-Guided Treatment Interruption.
 Seoane E, Resino S, Micheloud D, et al
 J Acquir Immune Defic Syndr. 2008 Jul 8.
Abstract
 
Interferon May Prevent HIV Viral Rebound After HAART Interruption in HIV Patients.
 Dianzani F, Rozera G, Abbate I, et al
 J Interferon Cytokine Res. 2008 Jan;28(1):1-3.
 Abstract
 
Virological Outcome After Structured Interruption of Antiretroviral Therapy For HIV Infection is
Associated with the Functional Profile of Virus-Specific CD8+ T-Cells.
 Daucher M, Price DA, Brenchley JM, et al 
J Virol. 2008 Jan 30
Abstract
 
Determinants of virologic and immunologic outcomes in chronically HIV-Infected subjects
undergoing repeated treatment interruptions: the Istituto Duperiore di Sanita-pulsed
antiretroviral therapy (ISS-PART) study.
Palmisano L, Giuliano M, Bucciardini R, et al 
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47.
 Abstract
 
CD4+ guided interruption HAART in HIV patients
Antolini D, Lanzafame M, Lattuada E, et al 
Recenti Prog Med. 2007 Oct;98(10):501-5.
 Abstract
 
Reappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment
interruption.
 Madsen TV, Gerstoft J, Nielsen C, Jørgensen LB. 
Scand J Infect Dis. 2007 Oct 10;:1-9
Abstract
 
Determinants of Virologic and Immunologic Outcome in Chronically HIV-Infected Subjects
Undergoing Repeated Treatment Interruptions: The Istituto Superiore di Sanità-Pulsed
Antiretroviral Therapy (ISS-PART) Study.
 Palmisano L, Giuliano M, Bucciardini R, et al
J Acquir Immune Defic Syndr. 2007 Jul 19;
 Abstract
 
Virological characterization of patients treated early is able to control HIV-1 replication after
multiple cycles of structured therapy interruption.
 Rozera G, Abbate I, D'Offizi G, et al  
J Med Virol. 2007 Jun 27;79(8):1047-1054
Abstract
 
Drug-Sparing Regimens for HIV Combination Therapy: Benefits Predicted for "Drug Coasting"
Krakovska O, Wahl LM
 Bull Math Biol. 2007 Jun 20
 Abstract
 
Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV
infection: findings from an observational cohort.
 Fidler S, Fox J, Touloumi G, et al 
AIDS. 2007 Jun;21(10):1283-1291.
 Abstract
 
A Prospective Randomized Controlled Trial of Structured Treatment Interruption in HIV-Infected
Patients Failing Highly Active Antiretroviral Therapy (Canadian HIV Trials Network Study 164).
 Walmsley SL, Thorne A, Loutfy MR, et al
Acquir Immune Defic Syndr. 2007 Apr 26;
 Abstract
 
Interruption of Antiretroviral Treatment in HIV-Infected Patients with Preserved Immune Function Is
Associated with a Low Rate of Clinical Progression: A Prospective Study by AIDS Clinical Trials
Group 5170.
 Skiest DJ, Su Z, Havlir DV, et al 
J Infect Dis. 2007 May 15;195(10):1426-36.
 Abstract
 
Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350
Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
 Pogany K, Vanvalkengoed IG, Prins JM, et al 
J Acquir Immune Defic Syndr. 2006 Dec 21
 Abstract
 
CD4+ count-guided interruption of antiretroviral treatment.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, et al 
N Engl J Med. 2006 Nov 30;355(22):2283-96.
 Abstract
 
A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons
with Drug-Resistant HIV: 48-Week Virologic Results of ACTG A5086.
 Benson CA, Vaida F, Havlir DV, et al 
J Infect Dis. 2006 Nov 1;194(9):1309-18
 Abstract
 
Structured treatment interruptions: after SMART.
Sledge M.
 BETA. 2006 Summer;18(4):30-6.
Abstract
 

FULL TEXT PDF ARTICLE
 Structured treatment interruptions--new findings.
 Benson CA
 Top HIV Med. 2006 Aug-Sep;14(3):107-11
 Abstract
 
Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC-
HIV vCP1452,Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group
5068.
Jacobson JM, Pat Bucy R, Spritzler J, et al
 J Infect Dis. 2006 Sep 1;194(5):623-32.
 Abstract
 
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with
HIV-1: results of the Staccato randomised trial.
 Ananworanich J, Gayet-Ageron A, Le Braz M, et al
 Lancet. 2006 Aug 5;368(9534):459-65.
 Abstract
 
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
Pai N, Lawrence J, Reingold A, Tulsky J. 
Cochrane Database Syst Rev. 2006 Jul 19;
 Abstract
 
Treatment interruptions in HIV-infected subjects.
Bongiovanni M, Casana M, Tincati C, d'Arminio Monforte A.  
J Antimicrob Chemother. 2006 Jul 1;
Abstract
 
Treatment Interruption in HIV Therapy: a SMART Strategy?
Julg B, Goebel FD.  
Infection. 2006 Jun;34(3):186-8.
Abstract
 
Structured Treatment Interruptions in Primary HIV-1 Infection: The ANRS 100 PRIMSTOP Trial.
Hoen B, Fournier I, Lacabaratz C,  et al
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):307-316.
 Abstract
 
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in
HIV-infected patients: a prospective study.
Mussini C, Pinti M, Bugarini R, Borghi V 
AIDS. 2005 Oct 14;19(15):1627-1633.
 Abstract

FULL-TEXT ARTICLE
 Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection
Papasavvas E,  Kostman JR,  Mounzer K,  et al
PLOS Medicine Vol2 Issue 9 Sep 2005
 Paper

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA
and > 400 CD4(+) cells/microl? Impact on immunovirological parameters.
 Pellegrin I, Thiebaut R, Blanco P, et al 
J Med Virol. 2005 Aug 24;77(2):164-172
 Abstract
 
Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly
active antiretroviral therapy is resumed after treatment interruption.
 Barreiro P, de Mendoza C, Gonzalez-Lahoz J, Soriano V.
Clin Infect Dis. 2005 Sep 15;41(6):897-900
Abstract
 
Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection:
A Pilot Study in Sao Paulo, Brazil.
Casseb J, Da Silva Duarte AJ.
AIDS Patient Care STDS. 2005 Jul;19(7):425-8.
 Abstract
 
Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided
Therapy Achieved Similar Virologic Suppression Compared With Patients on
Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration
001.4 Study.
 Ananworanich J, Siangphoe U, Hill A, et al 
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-529.
 Abstract
 
Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly
active antiretroviral treatment
Pavie J, Porcher R, Fournier S, et al 
Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13.
Abstract
 
Interruption of antiretroviral therapy in chronically HIV-infected patients.
 Amador C, Pasquau F, Ena J, Benito C, et al 
Med Clin (Barc). 2005 Jun 11;125(2):41-5
 Abstract
 
A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with
Chronic HIVType 1 Infection.
 Cardiello PG, Hassink E, Ananworanich J, et al   
Clin Infect Dis. 2005 Feb 15;40(4):594-600.
Abstract
 
Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice:
Results From the Italian Cohort of Antiretroviral-Naive Patients.
 Monforte AD, Cozzi-Lepri A, Phillips A, et al 
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):407-416.
 Abstract
 
Prolonged treatment interruption in chronic HIV infection: a new strategy?
 Giuntini R, Martinelli C, Ambu S, et al
AIDS. 2005 Jan 28;19(2):209-11.
 Abstract
 
Extended antiretroviral treatment interruption in HIV-infected patients with long-term
suppression of plasma HIV RNA.
 Achenbach C, Till M, Palella F 
HIV Med. 2005 Jan;6(1):7-12.
 Abstract
 
FULL-TEXT ARTICLE
Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection.
Papasavvas E, Kostman JR, Mounzer K, et al
PLoS Med. 2004 Dec;1(3):e64.
Paper

Immunological markers after long-term treatment interruption in chronically HIV-1 infected
patients with CD4 cell count above 400 x 106 cells/l.
 Thiebaut R, Pellegrin I, Chene G, et al  
 AIDS. 2005 Jan 3;19(1):53-61.
Abstract
 
CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good
response tohighly active antiretroviral therapy.
 Boschi A, Tinelli C, Ortolani P, et al 
AIDS. 2004 Dec 3;18(18):2381-9.
 Abstract
 
Antiretroviral drug treatment interruption in human immunodeficiency virus-infected
adults: Clinical and pathogenetic implications for the central nervous system.
 Price RW, Deeks SG. 
J Neurovirol. 2004;10 Suppl 1:44-51
 
Predictors of sustained response to therapy resumption after treatment interruption in HIV-
infected patients failing antiretroviral therapy.
 Gianotti N, Soria A, Galli L, et al.
 Med Virol. 2004 Feb;72(2):181-186.
 Abstract
 
Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of
highly active antiretroviral therapy initiated at acute infection combined with structured treatment
interruptions and immune-based therapies.
 Lafeuillade A, Poggi C, Hittinger G, et al 
J Infect Dis. 2003 Nov 15;188(10):1426-32.
 Abstract
 
Role of Structured Treatment Interruption before a 5-Drug Salvage Antiretroviral Regimen: The
Retrogene Study.
Ruiz L, Ribera E, Bonjoch A, et al
 J Infect Dis. 2003 Oct 1;188(7):977-8
 Abstract
 
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J, Mayers DL, Hullsiek KH, et al  
N Engl J Med. 2003 Aug 28;349(9):837-46.
 Abstract
 
Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the
Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and
on Immunologic and Virologic Parameters.
Dybul M, Nies-Kraske E, Daucher M, et al
J Infect Dis. 2003 Aug 1;188(3):388-96.
Abstract
 
Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has
No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring
Viruses with Mutations Associated with Resistance to NNRTIs.
Wirden M, Simon A, Schneider L, et al.
J Clin Microbiol. 2003 Jun;41(6):2713-5.
Abstract

HIV RNA in plasma rebounds within days during structured treatment interruptions.
Fischer M, Hafner R, Schneider C, et al
 AIDS 2003 Jan 24;17(2):195-9
 Abstract

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions:
a randomized study.
Garcia F, Plana M, Arnedo M, et al.
AIDS 2003 Jan 3;17(1):43-51
 Abstract

Planned interruptions of anti-HIV treatment.
Hirschel B.
Lancet Infect Dis 2001 Aug;1(1):53-9
 Abstract
 

  
Cytokine therapy or structured treatment interruptions in HIV infection: which is best?
Parienti JJ.
Expert Opin Pharmacother  2002 Jun;3(6):719-26  
Abstract
 
FULL-TEXT ARTICLE
 Short-cycle structured intermittent treatment of chronic HIV infection with highly active
antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters.
Dybul M, Chun TW, Yoder C, Hidalgo B, et al
Proc Natl Acad Sci U S A 2001 Dec 4;
 Paper
 
  FULL-TEXT ARTICLE
 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
Ortiz GM, Wellons M, Brancato J. et al
Proc Natl Acad Sci U S A 2001 Nov 6;98(23):13288-93
 Paper
Retrospective Studies
     
  Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-
infected patients: a review of recent clinical data and future prospects.
 Lori F, Foli A, Lisziewicz J.
J Antimicrob Chemother 2002 Aug;50(2):155-60
 Abstract
Diagnostics/Monitoring
     
  Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.
 Chilton D, Dervisevic S, Pillay D, et al
AIDS. 2005 Dec 2;19(18):2174-2175.
 Abstract
Viral Dynamics Studies
     
 
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
 Bar KJ, Sneller MC, Harrison LJ, et al
N Engl J Med. 2016 Nov 24;375(21):2037-2050..
 Abstract

Are previous treatment interruptions associated with higher viral rebound rates in patients
with viral suppression?
 Bansi LK, Benzie AA, Phillips AN, et al 
AIDS. 2008 Jan 30;22(3):349-56.
 Abstract
 

The Role of Hydroxyurea in Enhancing the Virologic Control Achieved through Structured
Treatment Interruption in Primary HIV Infection: Final Results from a Randomized Clinical
Trial (Pulse).
Bloch MT, Smith DE, Quan D, et al
J Acquir Immune Defic Syndr. 2006 May 8;
Abstract

Viral Evolution during Structured Treatment Interruptions in Chronically Human
Immunodeficiency Virus-Infected Individuals.
Martinez-Picado J, Frost SD, Izquierdo N, et al.
J Virol 2002 Dec 1;76(23):12344-12348
 Abstract

Virological and immunological effects of salvage therapy following treatment interruption  
and a shift in HIV-1resistance genotype.
 Izopet J, Souyris C, Sandres-Saune K, et al.
 J Med Virol 2002 Nov;68(3):305-10
 Abstract
 
Viral dynamics during structured treatment interruptions of chronic human immunodeficiency
virus  type 1 infection.
Frost SD, Martinez-Picado J, Ruiz L, et al.  
 J Virol 2002 Feb;76(3):968-79
 Abstract
 
FULL-TEXT ARTICLE
 Short-cycle structured intermittent treatment of chronic HIV infection with highly active
antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters.
Dybul M, Chun TW, Yoder C, Hidalgo B, et al
Proc Natl Acad Sci U S A 2001 Dec 4;
 Paper
 
The virological and immunological consequences of structured treatment interruptions in
chronic HIV-1 infection.
Garcia F, Plana M, Ortiz GM, et al.
AIDS 2001 Jun 15;15(9):F29-40
 Abstract
Resistance
     
 
Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment
Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M,  et al 
AIDS Res Hum Retroviruses. 2010 May 10
 Abstract

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting
a new therapy.
 Balduin M, Sierra S, Daumer MP, et al
J Clin Virol. 2005 Sep 24;
Abstract

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting
a new therapy.
 Balduin M, Sierra S, Daumer MP, et al
 J Clin Virol. 2005 Sep 24
 Abstract
Adverse Events
     
 
Effects of unplanned treatment interruptions on HIV treatment failure- results from TAHOD.
 Jiamsakul A, Kerr SJ, Ng OT,  et al
Trop Med Int Health. 2016 Mar 7
 Abstract

Antiretroviral Treatment Interruptions Predict Female Genital Shedding of Genotypically Resistant HIV-1 RNA.
Graham SM, Jalalian-Lechak Z, et al
J Acquir Immune Defic Syndr. 2012 May 15
 Abstract

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic
complications and death.
Kaufmann GR, Elzi L, Weber R,  et al
AIDS. 2011 Jan 3.
Abstract

Predictive Value of Intracellular HIV-1 DNA Levels During CD4-Guided
Treatment Interruption in HIV(+) Patients.
Nasi M, Pinti M, Manzini S, Gibellini L, et al
AIDS Res Hum Retroviruses. 2010 May 10
 Abstract

Neurocognitive effects of treatment interruption in stable HIV-positive patients
in an observational cohort.
Robertson KR, Su Z, Margolis DM, et al
Neurology. 2010 Mar 17. |
 Abstract

Antiretroviral Treatment Interruptions and Risk of Non-opportunistic Diseases.
 Lichtenstein KA.
Curr HIV/AIDS Rep. 2009 May;6(2):77-82.
 Abstract

Pneumonia in HIV-Infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption.
 Gordin FM, Roediger MP, Girard PM, et al
Am J Respir Crit Care Med. 2008 Jul 10.
Abstract
 
FULL TEXT ARTICLE
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection:
implications for cardiovascular risk.
 Tebas P, Henry WK, Matining R, Weng-Cherng D,
PLoS ONE. 2008 Apr 23;3(4):e2021.
 Paper

Interruption of combination antiretroviral therapy and risk of clinical disease progression
to AIDS or death.
Holkmann Olsen C, Mocroft A, et al
 HIV Med. 2007 Mar;8(2):96-104.
 Abstract
 
FULL-TEXT PDF ARTICLE
 Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in
HIV-1 infection.
 Gisslen M, Rosengren L, Hagberg L, et al   
AIDS Res Ther. 2005 Aug 18;2(1):6
 Paper
 
Symptomatic HIV viraemia during a drug holiday: an argument against treatment
interruption?
 Freedman E, Dhaliwal K, Estcourt C, et al  
Int J STD AIDS. 2004 Aug;15(8):564-5.
Abstract

A Case of Multiorgan Failure Following Interruption of Antiretroviral Treatment.
 Crespo M, Paradineiro JC, Ribera E, et al 
Eur J Clin Microbiol Infect Dis. 2003 Dec 11
 Abstract

Recurring thrombocytopenia associated with structured treatment interruption in patients
with human immunodeficiency virus infection.
 Ananworanich J, Phanuphak N, Nuesch R, et al
Clin Infect Dis. 2003 Sep 1;37(5):723-5.
Abstract
 
Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological
and virological consequences
 Sommet A, Delpierre C, Cuzin L, et al.
Rev Med Interne. 2003 Jun;24(6):350-7.
Abstract

Treament Interruption Main Page Main New/Newsworthy Home Page

Treatment Interruption